Both CD19- and BCMA-targeted CAR T-cells have been used in combination in a few trials [150]; for example, NCT03455972 (newly diagnosed MM) [148] and NCT03196414 [149] (RRMM). Here, CD19 is linked to Miyoshi myopathy.